Liraglutide (Saxenda) vs Semaglutide (Wegovy tablets)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Obesity

Shared mechanism: GLP-1 receptor · full Obesity pipeline

Liraglutide (Saxenda)

Marketed by Novo Nordisk

Approved in Obesitypeptide
Reliable signal

NCT00781937 · Phase 3 · completed

The trial randomly assigned 212 participants to liraglutide and 210 to placebo in a double-blind, placebo-controlled design, with objective body-weight outcomes assessed at week 56. All three prespecified primary comparisons favored liraglutide and were statistically significant (each p<0.0001), supporting a strong evidence grade.

Next expected readout: December 2026 · NCT07225816 (registry estimate)

Reported efficacy

Change in BMI SDS (Week 0, Week 56): Change in BMI SDS (Week 0, Week 56) (Week 0, week 56): Liraglutide 3.0 mg -0.25 SDS score (Standard Deviation 0.51) vs Placebo -0.02 SDS score (Standard Deviation 0.54) (met)

Result source: NCT02918279

Semaglutide (Wegovy tablets)

Marketed by Novo Nordisk

Approved in Obesitypeptide
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2026 · NCT07225816 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Obesity

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointLiraglutide (Saxenda)Semaglutide (Wegovy tablets)
Body weight, % change-8.0% vs -2.6%−5.4 vs placebo3.0 mg · wk 56 · n 2432NCT01272219
20 other results
  • -6.1% vs -0.1% 3.0 mg · wk 56 · n 194 · Phase 3 · primary NCT00781937
  • -5.9% vs -2% 3.0 mg · wk 56 · n 412 · Phase 3 · primary NCT01272232
  • -4.6% vs -2% 1.8 mg · wk 56 · n 204 · Phase 3 · primary NCT01272232
  • -7.7% vs -6.5% wk 12 · n 93 · Phase 3 · primary NCT03374956
  • -6.1% vs -1.9% 3.0 mg · wk 160 · n 1467 · Phase 3 · secondary NCT01272219
  • 0.7% vs 0.3% 3.0 mg · wk 68 · n 349 · Phase 3 · secondary NCT01272219
  • 2.9% vs 0.3% 3.0 mg · wk 68 · n 346 · Phase 3 · secondary NCT01272219
  • -8.4% vs -3.1% 3.0 mg · wk 68 · n 349 · Phase 3 · secondary NCT01272219
  • -6.8% vs -3.1% 3.0 mg · wk 68 · n 347 · Phase 3 · secondary NCT01272219
  • -4.7% vs -2.7% 3.0 mg · wk 68 · n 324 · Phase 3 · secondary NCT01272232
  • -3.6% vs -2.7% 1.8 mg · wk 68 · n 164 · Phase 3 · secondary NCT01272232
  • -5.7% vs -1.4% 3 mg · wk 32 · n 44 · Phase 3 · secondary NCT03480022
  • -0.4% vs 3.3% wk 52 · n 17 · Phase 3 · secondary NCT02527200
  • 6.3% vs 3.3% wk 52 · n 14 · Phase 3 · secondary NCT02527200
  • 2.6% vs 3.3% wk 52 · n 31 · Phase 3 · secondary NCT02527200
  • -1.7% vs -1.2% wk 16 · n 18 · Phase 3 · secondary NCT02527200
  • -1.1% vs -1.2% wk 16 · n 16 · Phase 3 · secondary NCT02527200
  • -1.4% vs -1.2% wk 16 · n 34 · Phase 3 · secondary NCT02527200
  • -3.3% vs 0.2% wk 40 · n 29 · Phase 2 · primary NCT03158805
  • -6.6% vs -1.2% 3.0 mg · wk 40 · n 73 · Phase 4 · secondary NCT03038620
-14.9% vs -1.5%−13.4 vs placebo50 mg · wk 68 · n 127NCT05132088
2 other results
  • -15.8% vs -2.2% 50 mg once daily · wk 68 · n 317 · Phase 3 · primary NCT05035095
  • -14.4% vs -2.5% 25 mg once daily · wk 64 · n 192 · Phase 3 · primary NCT05564117
Weight loss of 5% or more63.2% vs 27.1%+36.1 vs placebo3.0 mg · wk 56 · n 2432NCT01272219
4 other results
  • 50.5% vs 21.9% 3.0 mg · wk 56 · n 194 · Phase 3 · primary NCT00781937
  • 49.9% vs 13.8% 3.0 mg · wk 56 · n 412 · Phase 3 · primary NCT01272232
  • 35.6% vs 13.8% 1.8 mg · wk 56 · n 204 · Phase 3 · primary NCT01272232
  • 76% vs 17% wk 52 · n 58 · Phase 4 · primary NCT03048578
—Not posted · NCT05890976
Weight loss of 10% or more33.1% vs 10.6%+22.5 vs placebo3.0 mg · wk 56 · n 2432NCT01272219
3 other results
  • 23.4% vs 4.3% 3.0 mg · wk 56 · n 412 · Phase 3 · primary NCT01272232
  • 14.4% vs 4.3% 1.8 mg · wk 56 · n 204 · Phase 3 · primary NCT01272232
  • 26.1% vs 6.3% 3.0 mg · wk 56 · n 194 · Phase 3 · secondary NCT00781937
—Not posted · NCT05890976
Waist circumference, change (cm)-8.2 vs -3.9−4.2 vs placebo3.0 mg · wk 56 · n 2437NCT01272219
24 other results
  • -6.9 vs -3.4 3.0 mg · wk 160 · n 1472 · Phase 3 · secondary NCT01272219
  • -5.7 vs -3.2 3.0 mg · wk 68 · n 324 · Phase 3 · secondary NCT01272232
  • -4.4 vs -0.9 3.0 mg · wk 56 · n 207 · Phase 3 · secondary NCT00781937
  • -6.1 vs -2.7 3.0 mg · wk 56 · n 412 · Phase 3 · secondary NCT01272232
  • -4.4 vs -3.2 1.8 mg · wk 68 · n 164 · Phase 3 · secondary NCT01272232
  • -4.8 vs -2.7 1.8 mg · wk 56 · n 204 · Phase 3 · secondary NCT01272232
  • 100.9 vs 109.9 3 mg · wk 32 · n 44 · Phase 3 · secondary NCT03480022
  • -3.0 vs -2.1 wk 52 · n 17 · Phase 3 · secondary NCT02527200
  • 0.5 vs -2.1 wk 52 · n 13 · Phase 3 · secondary NCT02527200
  • -1.5 vs -2.1 wk 52 · n 30 · Phase 3 · secondary NCT02527200
  • -2.5 vs -1.9 wk 16 · n 18 · Phase 3 · secondary NCT02527200
  • -0.7 vs -1.9 wk 16 · n 15 · Phase 3 · secondary NCT02527200
  • -1.7 vs -1.9 wk 16 · n 33 · Phase 3 · secondary NCT02527200
  • -7.4 vs -4.6 3.0 mg · wk 40 · n 73 · Phase 4 · secondary NCT03038620
  • -9.8 vs -9.5 3.0 mg · wk 104 · n 47 · Phase 2 · secondary NCT00422058
  • -7.9 vs -6 3.0 mg · wk 20 · n 85 · Phase 2 · secondary NCT00422058
  • -9 vs -9.5 1.8 mg / 3.0 mg · wk 104 · n 38 · Phase 2 · secondary NCT00422058
  • -5.9 vs -6 1.8 mg / 3.0 mg · wk 20 · n 83 · Phase 2 · secondary NCT00422058
  • -10 vs -9.5 placebo / 2.4 mg / 3.0 mg · wk 104 · n 47 · Phase 2 · secondary NCT00422058
  • -10.4 vs -9.5 2.4 mg / 3.0 mg · wk 104 · n 45 · Phase 2 · secondary NCT00422058
  • -4.2 vs -6 placebo / 2.4 mg / 3.0 mg · wk 20 · n 90 · Phase 2 · secondary NCT00422058
  • -7.2 vs -6 2.4 mg / 3.0 mg · wk 20 · n 85 · Phase 2 · secondary NCT00422058
  • -8.6 vs -9.5 1.2 mg / 3.0 mg · wk 104 · n 46 · Phase 2 · secondary NCT00422058
  • -5.8 vs -6 1.2 mg / 3.0 mg · wk 20 · n 93 · Phase 2 · secondary NCT00422058
-11.2 vs -1.4−9.8 vs placebo50 mg · wk 68 · n 127NCT05132088
2 other results
  • -13.4 vs -2.8 50 mg once daily · wk 68 · n 317 · Phase 3 · secondary NCT05035095
  • -12.9 vs -3.1 25 mg once daily · wk 64 · n 191 · Phase 3 · secondary NCT05564117

Body weight, % change

Liraglutide (Saxenda)
-8.0% vs -2.6%−5.4 vs placebo3.0 mg · wk 56 · n 2432NCT01272219
20 other results
  • -6.1% vs -0.1% 3.0 mg · wk 56 · n 194 · Phase 3 · primary NCT00781937
  • -5.9% vs -2% 3.0 mg · wk 56 · n 412 · Phase 3 · primary NCT01272232
  • -4.6% vs -2% 1.8 mg · wk 56 · n 204 · Phase 3 · primary NCT01272232
  • -7.7% vs -6.5% wk 12 · n 93 · Phase 3 · primary NCT03374956
  • -6.1% vs -1.9% 3.0 mg · wk 160 · n 1467 · Phase 3 · secondary NCT01272219
  • 0.7% vs 0.3% 3.0 mg · wk 68 · n 349 · Phase 3 · secondary NCT01272219
  • 2.9% vs 0.3% 3.0 mg · wk 68 · n 346 · Phase 3 · secondary NCT01272219
  • -8.4% vs -3.1% 3.0 mg · wk 68 · n 349 · Phase 3 · secondary NCT01272219
  • -6.8% vs -3.1% 3.0 mg · wk 68 · n 347 · Phase 3 · secondary NCT01272219
  • -4.7% vs -2.7% 3.0 mg · wk 68 · n 324 · Phase 3 · secondary NCT01272232
  • -3.6% vs -2.7% 1.8 mg · wk 68 · n 164 · Phase 3 · secondary NCT01272232
  • -5.7% vs -1.4% 3 mg · wk 32 · n 44 · Phase 3 · secondary NCT03480022
  • -0.4% vs 3.3% wk 52 · n 17 · Phase 3 · secondary NCT02527200
  • 6.3% vs 3.3% wk 52 · n 14 · Phase 3 · secondary NCT02527200
  • 2.6% vs 3.3% wk 52 · n 31 · Phase 3 · secondary NCT02527200
  • -1.7% vs -1.2% wk 16 · n 18 · Phase 3 · secondary NCT02527200
  • -1.1% vs -1.2% wk 16 · n 16 · Phase 3 · secondary NCT02527200
  • -1.4% vs -1.2% wk 16 · n 34 · Phase 3 · secondary NCT02527200
  • -3.3% vs 0.2% wk 40 · n 29 · Phase 2 · primary NCT03158805
  • -6.6% vs -1.2% 3.0 mg · wk 40 · n 73 · Phase 4 · secondary NCT03038620
Semaglutide (Wegovy tablets)
-14.9% vs -1.5%−13.4 vs placebo50 mg · wk 68 · n 127NCT05132088
2 other results
  • -15.8% vs -2.2% 50 mg once daily · wk 68 · n 317 · Phase 3 · primary NCT05035095
  • -14.4% vs -2.5% 25 mg once daily · wk 64 · n 192 · Phase 3 · primary NCT05564117

Weight loss of 5% or more

Liraglutide (Saxenda)
63.2% vs 27.1%+36.1 vs placebo3.0 mg · wk 56 · n 2432NCT01272219
4 other results
  • 50.5% vs 21.9% 3.0 mg · wk 56 · n 194 · Phase 3 · primary NCT00781937
  • 49.9% vs 13.8% 3.0 mg · wk 56 · n 412 · Phase 3 · primary NCT01272232
  • 35.6% vs 13.8% 1.8 mg · wk 56 · n 204 · Phase 3 · primary NCT01272232
  • 76% vs 17% wk 52 · n 58 · Phase 4 · primary NCT03048578
Semaglutide (Wegovy tablets)
—Not posted · NCT05890976

Weight loss of 10% or more

Liraglutide (Saxenda)
33.1% vs 10.6%+22.5 vs placebo3.0 mg · wk 56 · n 2432NCT01272219
3 other results
  • 23.4% vs 4.3% 3.0 mg · wk 56 · n 412 · Phase 3 · primary NCT01272232
  • 14.4% vs 4.3% 1.8 mg · wk 56 · n 204 · Phase 3 · primary NCT01272232
  • 26.1% vs 6.3% 3.0 mg · wk 56 · n 194 · Phase 3 · secondary NCT00781937
Semaglutide (Wegovy tablets)
—Not posted · NCT05890976

Waist circumference, change (cm)

Liraglutide (Saxenda)
-8.2 vs -3.9−4.2 vs placebo3.0 mg · wk 56 · n 2437NCT01272219
24 other results
  • -6.9 vs -3.4 3.0 mg · wk 160 · n 1472 · Phase 3 · secondary NCT01272219
  • -5.7 vs -3.2 3.0 mg · wk 68 · n 324 · Phase 3 · secondary NCT01272232
  • -4.4 vs -0.9 3.0 mg · wk 56 · n 207 · Phase 3 · secondary NCT00781937
  • -6.1 vs -2.7 3.0 mg · wk 56 · n 412 · Phase 3 · secondary NCT01272232
  • -4.4 vs -3.2 1.8 mg · wk 68 · n 164 · Phase 3 · secondary NCT01272232
  • -4.8 vs -2.7 1.8 mg · wk 56 · n 204 · Phase 3 · secondary NCT01272232
  • 100.9 vs 109.9 3 mg · wk 32 · n 44 · Phase 3 · secondary NCT03480022
  • -3.0 vs -2.1 wk 52 · n 17 · Phase 3 · secondary NCT02527200
  • 0.5 vs -2.1 wk 52 · n 13 · Phase 3 · secondary NCT02527200
  • -1.5 vs -2.1 wk 52 · n 30 · Phase 3 · secondary NCT02527200
  • -2.5 vs -1.9 wk 16 · n 18 · Phase 3 · secondary NCT02527200
  • -0.7 vs -1.9 wk 16 · n 15 · Phase 3 · secondary NCT02527200
  • -1.7 vs -1.9 wk 16 · n 33 · Phase 3 · secondary NCT02527200
  • -7.4 vs -4.6 3.0 mg · wk 40 · n 73 · Phase 4 · secondary NCT03038620
  • -9.8 vs -9.5 3.0 mg · wk 104 · n 47 · Phase 2 · secondary NCT00422058
  • -7.9 vs -6 3.0 mg · wk 20 · n 85 · Phase 2 · secondary NCT00422058
  • -9 vs -9.5 1.8 mg / 3.0 mg · wk 104 · n 38 · Phase 2 · secondary NCT00422058
  • -5.9 vs -6 1.8 mg / 3.0 mg · wk 20 · n 83 · Phase 2 · secondary NCT00422058
  • -10 vs -9.5 placebo / 2.4 mg / 3.0 mg · wk 104 · n 47 · Phase 2 · secondary NCT00422058
  • -10.4 vs -9.5 2.4 mg / 3.0 mg · wk 104 · n 45 · Phase 2 · secondary NCT00422058
  • -4.2 vs -6 placebo / 2.4 mg / 3.0 mg · wk 20 · n 90 · Phase 2 · secondary NCT00422058
  • -7.2 vs -6 2.4 mg / 3.0 mg · wk 20 · n 85 · Phase 2 · secondary NCT00422058
  • -8.6 vs -9.5 1.2 mg / 3.0 mg · wk 104 · n 46 · Phase 2 · secondary NCT00422058
  • -5.8 vs -6 1.2 mg / 3.0 mg · wk 20 · n 93 · Phase 2 · secondary NCT00422058
Semaglutide (Wegovy tablets)
-11.2 vs -1.4−9.8 vs placebo50 mg · wk 68 · n 127NCT05132088
2 other results
  • -13.4 vs -2.8 50 mg once daily · wk 68 · n 317 · Phase 3 · secondary NCT05035095
  • -12.9 vs -3.1 25 mg once daily · wk 64 · n 191 · Phase 3 · secondary NCT05564117
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
16 other shared endpoints and safety

Coverage. Liraglutide (Saxenda): 20 of 20 rows · Semaglutide (Wegovy tablets): 19 of 20 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricLiraglutide (Saxenda)
Rows use multiple source trials
Semaglutide (Wegovy tablets)
Rows use multiple source trials
BMI
absolute change · kg
-1.9 vs 0.15 placebo kg @ 56wk3.0 mga,b,c
NCT00781937 · Phase 3 · monotherapy · Obesity · phase 3
-4.89 vs -0.47 placebo kg @ 68wk50 mga,b,c
NCT05132088 · Phase 3 · registry result, not featured evidence
1 other source trial
-5.9 vs -0.9 placebo kg @ 68wk50 mg once daily
NCT05035095 · Phase 3 · registry result, not featured evidence
DBP
absolute change · mmHg
-1 vs -1 placebo mmHg @ 56wk3.0 mga,b,c
NCT02963935 · Phase 3 · registry result, not featured evidence
-6 vs -1 placebo mmHg @ 68wk50 mga,b,c
NCT05132088 · Phase 3 · registry result, not featured evidence
1 other source trial
-2 vs -1 placebo mmHg @ 68wk50 mg once daily
NCT05035095 · Phase 3 · registry result, not featured evidence
Fasting Plasma Glucose
absolute change · mmol/L
-0.23 vs 0.02 Orlistat mmol/L @ 104wk3.0 mgd,e,a,b,f
NCT00422058 · Phase 2 · registry result, not featured evidence
show 4 more doses
-0.09 vs 0.02 Orlistat mmol/L @ 104wk1.8 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
-0.2 vs 0.02 Orlistat mmol/L @ 104wk2.4 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
-0.22 vs 0.02 Orlistat mmol/L @ 104wkplacebo / 2.4 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
-0.09 vs 0.02 Orlistat mmol/L @ 104wk1.2 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
-0.41 vs 0.01 placebo mmol/L @ 64wk*25 mg once dailye,a,b,f
NCT05564117 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -7.3 mg/dL as posted
Free Fatty Acids
absolute change · ratio
1.15 vs 1.45 placebo ratio @ 52wkd,g,h
NCT02527200 · Phase 3 · registry result, not featured evidence
show 2 more doses
1.01 vs 1.45 placebo ratio @ 52wk
NCT02527200 · Phase 3 · registry result, not featured evidence · combination
0.85 vs 1.45 placebo ratio @ 52wk
NCT02527200 · Phase 3 · registry result, not featured evidence
0.87 vs 1 placebo ratio @ 68wk50 mg once dailyg,h
NCT05035095 · Phase 3 · registry result, not featured evidence
HbA1c
absolute change · percentage points
-0.35% (n=47) vs -0.18% (n=45) Orlistat @ 104wk3.0 mgd,e,a,b,i
NCT00422058 · Phase 2 · registry result, not featured evidence
show 4 more doses
-0.3% (n=36) vs -0.18% (n=45) Orlistat @ 104wk1.8 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
-0.25% (n=45) vs -0.18% (n=45) Orlistat @ 104wk2.4 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
-0.32% (n=46) vs -0.18% (n=45) Orlistat @ 104wkplacebo / 2.4 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
-0.25% (n=45) vs -0.18% (n=45) Orlistat @ 104wk1.2 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
-0.8% (n=126) vs 0% (n=64) placebo @ 68wk50 mge,a,b,i
NCT05132088 · Phase 3 · registry result, not featured evidence
1 other source trial
-0.2% (n=311) vs 0.1% (n=286) placebo @ 68wk50 mg once daily
NCT05035095 · Phase 3 · registry result, not featured evidence
HDL-C
absolute change · ratio
0.99 vs 1.02 placebo ratio @ 52wkd,g,h
NCT02527200 · Phase 3 · registry result, not featured evidence
show 2 more doses
1.02 vs 1.02 placebo ratio @ 52wk
NCT02527200 · Phase 3 · registry result, not featured evidence · combination
1.06 vs 1.02 placebo ratio @ 52wk
NCT02527200 · Phase 3 · registry result, not featured evidence
1.07 vs 1.03 placebo ratio @ 68wk50 mgg,h
NCT05132088 · Phase 3 · registry result, not featured evidence
1 other source trial
1.05 vs 1.01 placebo ratio @ 68wk50 mg once daily
NCT05035095 · Phase 3 · registry result, not featured evidence
IWQOL-Lite-CT Physical Function
responder rate · % of participants
25.3% (n=198) vs 24.2% (n=198) placebo @ 56wk3.0 mgj,k,b,c
NCT02963922 · Phase 3 · registry result, not featured evidence
1 other source trial
37.3% (n=142) vs 34.3% (n=140) placebo @ 56wk3.0 mg
NCT02963935 · Phase 3 · registry result, not featured evidence
50% (n=298) vs 31.3% (n=278) placebo @ 68wk*50 mg once dailyj,k,b,c
Yes
NCT05035095 · Phase 3 · registry result, not featured evidence · converted to % from 149 Participants as posted
LDL-C
absolute change · ratio
1.02 vs 1.12 placebo ratio @ 52wkd,g,h
NCT02527200 · Phase 3 · registry result, not featured evidence
show 2 more doses
1.01 vs 1.12 placebo ratio @ 52wk
NCT02527200 · Phase 3 · registry result, not featured evidence · combination
0.99 vs 1.12 placebo ratio @ 52wk
NCT02527200 · Phase 3 · registry result, not featured evidence
0.89 vs 1.02 placebo ratio @ 68wk50 mgg,h
NCT05132088 · Phase 3 · registry result, not featured evidence
1 other source trial
0.98 vs 1.03 placebo ratio @ 68wk50 mg once daily
NCT05035095 · Phase 3 · registry result, not featured evidence
SBP
absolute change · mmHg
-2 vs -1 placebo mmHg @ 56wk3.0 mga,b,c
NCT02963935 · Phase 3 · registry result, not featured evidence
-11 vs -2 placebo mmHg @ 68wk50 mga,b,c
NCT05132088 · Phase 3 · registry result, not featured evidence
1 other source trial
-7 vs -1 placebo mmHg @ 68wk50 mg once daily
NCT05035095 · Phase 3 · registry result, not featured evidence
SF-36 Physical Functioning
responder rate · % of participants
28.8% (n=198) vs 26.3% (n=198) placebo @ 56wk3.0 mgj,k,b,c
NCT02963922 · Phase 3 · registry result, not featured evidence
1 other source trial
38.7% (n=142) vs 37.9% (n=140) placebo @ 56wk3.0 mg
NCT02963935 · Phase 3 · registry result, not featured evidence
37.3% (n=303) vs 20% (n=280) placebo @ 68wk*50 mg once dailyj,k,b,c
Yes
NCT05035095 · Phase 3 · registry result, not featured evidence · converted to % from 113 Participants as posted
Total Cholesterol
absolute change · ratio
1 vs 1.06 placebo ratio @ 52wkd,g,h
NCT02527200 · Phase 3 · registry result, not featured evidence
show 2 more doses
1.01 vs 1.06 placebo ratio @ 52wk
NCT02527200 · Phase 3 · registry result, not featured evidence · combination
1.01 vs 1.06 placebo ratio @ 52wk
NCT02527200 · Phase 3 · registry result, not featured evidence
0.92 vs 1.02 placebo ratio @ 68wk50 mgg,h
NCT05132088 · Phase 3 · registry result, not featured evidence
1 other source trial
0.97 vs 1.01 placebo ratio @ 68wk50 mg once daily
NCT05035095 · Phase 3 · registry result, not featured evidence
Triglycerides
absolute change · ratio
1.07 vs 0.94 placebo ratio @ 52wkd,g,h
NCT02527200 · Phase 3 · registry result, not featured evidence
show 2 more doses
1.06 vs 0.94 placebo ratio @ 52wk
NCT02527200 · Phase 3 · registry result, not featured evidence · combination
1.04 vs 0.94 placebo ratio @ 52wk
NCT02527200 · Phase 3 · registry result, not featured evidence
0.73 vs 0.99 placebo ratio @ 68wk50 mgg,h
NCT05132088 · Phase 3 · registry result, not featured evidence
1 other source trial
0.77 vs 0.96 placebo ratio @ 68wk50 mg once daily
NCT05035095 · Phase 3 · registry result, not featured evidence
VLDL-C
absolute change · ratio
1.06 vs 0.95 placebo ratio @ 52wkd,g,h
NCT02527200 · Phase 3 · registry result, not featured evidence
show 2 more doses
1.04 vs 0.95 placebo ratio @ 52wk
NCT02527200 · Phase 3 · registry result, not featured evidence · combination
1.03 vs 0.95 placebo ratio @ 52wk
NCT02527200 · Phase 3 · registry result, not featured evidence
0.74 vs 0.99 placebo ratio @ 68wk50 mgg,h
NCT05132088 · Phase 3 · registry result, not featured evidence
1 other source trial
0.77 vs 0.96 placebo ratio @ 68wk50 mg once daily
NCT05035095 · Phase 3 · registry result, not featured evidence
Weight
absolute change · kg
-3.83 vs 0.41 placebo kg @ 68wk3.0 mga,b
NCT00781937 · Phase 3 · monotherapy · Obesity · phase 3
-16.1 vs -2.4 placebo kg @ 68wk50 mg once dailya,b
NCT05035095 · Phase 3 · registry result, not featured evidence
Weight Loss 10%
event count · % of participants
29.5% (n=44) vs 8.7% (n=23) placebo @ 32wk*3 mgj,l,b,m
NCT03480022 · Phase 3 · registry result, not featured evidence · converted to % from 13 Participants as posted
65.4% (n=127) vs 9.4% (n=64) placebo @ 68wk*50 mgj,l,b,m
Yes
NCT05132088 · Phase 3 · registry result, not featured evidence · converted to % from 83 Participants as posted
1 other source trial
69.4% (n=317) vs 11.9% (n=295) placebo @ 68wk*50 mg once daily
Yes
NCT05035095 · Phase 3 · registry result, not featured evidence · converted to % from 220 Participants as posted
Weight Loss 5%
event count · % of participants
56.8% (n=44) vs 21.7% (n=23) placebo @ 32wk*3 mgj,l,b,m
NCT03480022 · Phase 3 · registry result, not featured evidence · converted to % from 25 Participants as posted
84.3% (n=127) vs 17.2% (n=64) placebo @ 68wk*50 mgj,l,b,m
Yes
NCT05132088 · Phase 3 · registry result, not featured evidence · converted to % from 107 Participants as posted
1 other source trial
84.9% (n=317) vs 25.8% (n=295) placebo @ 68wk*50 mg once daily
Yes
NCT05035095 · Phase 3 · registry result, not featured evidence · converted to % from 269 Participants as posted
Dropout rate
25%3.0 mgn
NCT00781937 · Phase 3 · monotherapy · Obesity · phase 3
show 38 more results
27.4%3.0 mg
NCT01272219 · Phase 3 · Obesity · phase 3
29.2%3.0 mg
NCT01272219 · Phase 3 · Obesity · phase 3
—3.0 mg
NCT01272219 · Phase 3 · monotherapy · Obesity · phase 3
—3.0 mg
NCT01272219 · Phase 3 · Obesity · phase 3
23.4%3.0 mg
NCT01272232 · Phase 3 · Obesity, Type 2 Diabetes · phase 3
22.3%1.8 mg
NCT01272232 · Phase 3 · Obesity, Type 2 Diabetes · phase 3
25.6%3.0 mg
NCT01557166 · Phase 3 · monotherapy · Obesity · phase 3
10.4%3.0 mg
NCT02918279 · Phase 3
22.7%3 mg
NCT03036800 · Phase 4 · registry result, not featured evidence · combination
34.8%
NCT03048578 · Phase 4 · registry result, not featured evidence
20.7%3.0 mg
NCT03038620 · Phase 4 · registry result, not featured evidence
10%
NCT02911818 · Phase 4 · registry result, not featured evidence
—
NCT01562678 · Phase 4 · registry result, not featured evidence
0%
NCT03115424 · Phase 3 · registry result, not featured evidence
0%
NCT03374956 · Phase 3 · registry result, not featured evidence · Obesity · phase 3
20%3 mg
NCT03480022 · Phase 3 · registry result, not featured evidence
15%Part A: Liraglutide
NCT02527200 · Phase 3 · registry result, not featured evidence
11.8%Part B: Liraglutide
NCT02527200 · Phase 3 · registry result, not featured evidence
16.2%3.0 mg
NCT02963922 · Phase 3 · registry result, not featured evidence
—3.0 mg
NCT02963935 · Phase 3 · registry result, not featured evidence
19.7%3.0 mg
NCT02963935 · Phase 3 · registry result, not featured evidence
31.4%
NCT01784965 · Phase 3 · registry result, not featured evidence
8.8%
NCT04883346 · Phase 2 · registry result, not featured evidence
55.2%
NCT03158805 · Phase 2 · registry result, not featured evidence
11.9%
NCT03523273 · Phase 2 · registry result, not featured evidence
10.5%
NCT02647944 · Phase 2 · registry result, not featured evidence
11.8%3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
17.8%1.8 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
21.5%2.4 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
19.4%placebo / 2.4 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
10.5%1.2 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
16.7%420 mg
NCT03757130 · Phase 1 · registry result, not featured evidence
16.7%AMG 598 420 mg + Liraglutide
NCT03757130 · Phase 1 · registry result, not featured evidence · combination
0%210 mg
NCT03757130 · Phase 1 · registry result, not featured evidence
0%AMG 598 210 mg + Liraglutide
NCT03757130 · Phase 1 · registry result, not featured evidence · combination
0%70 mg
NCT03757130 · Phase 1 · registry result, not featured evidence
12.5%AMG 598 70 mg + Liraglutide
NCT03757130 · Phase 1 · registry result, not featured evidence · combination
12.5%
NCT03041792 · Phase 1 · registry result, not featured evidence
4.4%25 mg once dailyo
NCT05564117 · Phase 3 · registry result, not featured evidence
show 2 more results
3%50 mg
NCT05132088 · Phase 3 · registry result, not featured evidence
4.2%50 mg once daily
NCT05035095 · Phase 3 · registry result, not featured evidence
Discontinued due to AEs
8.5%3.0 mgn
NCT00781937 · Phase 3 · monotherapy · Obesity · phase 3
show 38 more results
9.9%3.0 mg
NCT01272219 · Phase 3 · Obesity · phase 3
9%3.0 mg
NCT01272219 · Phase 3 · Obesity · phase 3
—3.0 mg
NCT01272219 · Phase 3 · monotherapy · Obesity · phase 3
—3.0 mg
NCT01272219 · Phase 3 · Obesity · phase 3
9.2%3.0 mg
NCT01272232 · Phase 3 · Obesity, Type 2 Diabetes · phase 3
8.5%1.8 mg
NCT01272232 · Phase 3 · Obesity, Type 2 Diabetes · phase 3
11.1%3.0 mg
NCT01557166 · Phase 3 · monotherapy · Obesity · phase 3
—3.0 mg
NCT02918279 · Phase 3
—3 mg
NCT03036800 · Phase 4 · registry result, not featured evidence · combination
1.1%
NCT03048578 · Phase 4 · registry result, not featured evidence
—3.0 mg
NCT03038620 · Phase 4 · registry result, not featured evidence
—
NCT02911818 · Phase 4 · registry result, not featured evidence
—
NCT01562678 · Phase 4 · registry result, not featured evidence
—
NCT03115424 · Phase 3 · registry result, not featured evidence
—
NCT03374956 · Phase 3 · registry result, not featured evidence · Obesity · phase 3
10.9%3 mg
NCT03480022 · Phase 3 · registry result, not featured evidence
—Part A: Liraglutide
NCT02527200 · Phase 3 · registry result, not featured evidence
—Part B: Liraglutide
NCT02527200 · Phase 3 · registry result, not featured evidence
7.6%3.0 mg
NCT02963922 · Phase 3 · registry result, not featured evidence
—3.0 mg
NCT02963935 · Phase 3 · registry result, not featured evidence
8.5%3.0 mg
NCT02963935 · Phase 3 · registry result, not featured evidence
22.9%
NCT01784965 · Phase 3 · registry result, not featured evidence
—
NCT04883346 · Phase 2 · registry result, not featured evidence
—
NCT03158805 · Phase 2 · registry result, not featured evidence
—
NCT03523273 · Phase 2 · registry result, not featured evidence
10.5%
NCT02647944 · Phase 2 · registry result, not featured evidence
5.4%3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
5.6%1.8 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
9.7%2.4 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
3.1%placebo / 2.4 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
4.2%1.2 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
—420 mg
NCT03757130 · Phase 1 · registry result, not featured evidence
—AMG 598 420 mg + Liraglutide
NCT03757130 · Phase 1 · registry result, not featured evidence · combination
—210 mg
NCT03757130 · Phase 1 · registry result, not featured evidence
—AMG 598 210 mg + Liraglutide
NCT03757130 · Phase 1 · registry result, not featured evidence · combination
—70 mg
NCT03757130 · Phase 1 · registry result, not featured evidence
—AMG 598 70 mg + Liraglutide
NCT03757130 · Phase 1 · registry result, not featured evidence · combination
12.5%
NCT03041792 · Phase 1 · registry result, not featured evidence
—25 mg once dailyo
NCT05564117 · Phase 3 · registry result, not featured evidence
show 2 more results
—50 mg
NCT05132088 · Phase 3 · registry result, not featured evidence
—50 mg once daily
NCT05035095 · Phase 3 · registry result, not featured evidence
Serious AEs
4.2%3.0 mgn
NCT00781937 · Phase 3 · monotherapy · Obesity · phase 3
show 38 more results
15.1%3.0 mg
NCT01272219 · Phase 3 · Obesity · phase 3
6.2%3.0 mg
NCT01272219 · Phase 3 · Obesity · phase 3
—3.0 mg
NCT01272219 · Phase 3 · monotherapy · Obesity · phase 3
—3.0 mg
NCT01272219 · Phase 3 · Obesity · phase 3
8.8%3.0 mg
NCT01272232 · Phase 3 · Obesity, Type 2 Diabetes · phase 3
8.6%1.8 mg
NCT01272232 · Phase 3 · Obesity, Type 2 Diabetes · phase 3
3.4%3.0 mg
NCT01557166 · Phase 3 · monotherapy · Obesity · phase 3
2.4%3.0 mg
NCT02918279 · Phase 3
16.5%3 mg
NCT03036800 · Phase 4 · registry result, not featured evidence · combination
4.5%
NCT03048578 · Phase 4 · registry result, not featured evidence
0%3.0 mg
NCT03038620 · Phase 4 · registry result, not featured evidence
0%
NCT02911818 · Phase 4 · registry result, not featured evidence
0%
NCT01562678 · Phase 4 · registry result, not featured evidence
8.3%
NCT03115424 · Phase 3 · registry result, not featured evidence
0%
NCT03374956 · Phase 3 · registry result, not featured evidence · Obesity · phase 3
0%3 mg
NCT03480022 · Phase 3 · registry result, not featured evidence
5%Part A: Liraglutide
NCT02527200 · Phase 3 · registry result, not featured evidence
11.8%Part B: Liraglutide
NCT02527200 · Phase 3 · registry result, not featured evidence
8.2%3.0 mg
NCT02963922 · Phase 3 · registry result, not featured evidence
4.2%3.0 mg
NCT02963935 · Phase 3 · registry result, not featured evidence
—3.0 mg
NCT02963935 · Phase 3 · registry result, not featured evidence
22.9%
NCT01784965 · Phase 3 · registry result, not featured evidence
0%
NCT04883346 · Phase 2 · registry result, not featured evidence
0%
NCT03158805 · Phase 2 · registry result, not featured evidence
1.5%
NCT03523273 · Phase 2 · registry result, not featured evidence
0%
NCT02647944 · Phase 2 · registry result, not featured evidence
10.8%3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
11.1%1.8 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
7.5%2.4 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
6.1%placebo / 2.4 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
9.5%1.2 mg / 3.0 mg
NCT00422058 · Phase 2 · registry result, not featured evidence
0%420 mg
NCT03757130 · Phase 1 · registry result, not featured evidence
0%AMG 598 420 mg + Liraglutide
NCT03757130 · Phase 1 · registry result, not featured evidence · combination
0%210 mg
NCT03757130 · Phase 1 · registry result, not featured evidence
0%AMG 598 210 mg + Liraglutide
NCT03757130 · Phase 1 · registry result, not featured evidence · combination
0%70 mg
NCT03757130 · Phase 1 · registry result, not featured evidence
0%AMG 598 70 mg + Liraglutide
NCT03757130 · Phase 1 · registry result, not featured evidence · combination
0%
NCT03041792 · Phase 1 · registry result, not featured evidence
3.9%25 mg once dailyo
NCT05564117 · Phase 3 · registry result, not featured evidence
show 2 more results
6%50 mg
NCT05132088 · Phase 3 · registry result, not featured evidence
9.6%50 mg once daily
NCT05035095 · Phase 3 · registry result, not featured evidence
Most frequent reported AEs
3.0 mgn
nausea 47.6% (placebo 17.1%)
constipation 26.9% (placebo 12.4%)
diarrhoea 17.9% (placebo 12.4%)
NCT00781937 · Phase 3 · monotherapy · Obesity · phase 3
show 35 more results
3.0 mg
nausea 40.8% (placebo 17%)
nasopharyngitis 26.5% (placebo 27.8%)
diarrhoea 25.5% (placebo 14.2%)
NCT01272219 · Phase 3 · Obesity · phase 3
3.0 mg
nausea 43.7% (placebo 17%)
constipation 21.2% (placebo 11.3%)
diarrhoea 21% (placebo 14.2%)
NCT01272219 · Phase 3 · Obesity · phase 3
3.0 mg
hypoglycaemia 44.3% (placebo 27.8%)
nausea 32.7% (placebo 13.7%)
diarrhoea 25.6% (placebo 12.7%)
NCT01272232 · Phase 3 · Obesity, Type 2 Diabetes · phase 3
1.8 mg
hypoglycaemia 40% (placebo 27.8%)
nausea 31.4% (placebo 13.7%)
diarrhoea 17.6% (placebo 12.7%)
NCT01272232 · Phase 3 · Obesity, Type 2 Diabetes · phase 3
3.0 mg
nausea 26.7% (placebo 6.7%)
diarrhoea 16.5% (placebo 7.8%)
headache 14.2% (placebo 11.2%)
NCT01557166 · Phase 3 · monotherapy · Obesity · phase 3
3.0 mg
nausea 42.4% (placebo 14.3%)
vomiting 34.4% (placebo 4%)
nasopharyngitis 27.2% (placebo 30.2%)
NCT02918279 · Phase 3
3 mg
nausea 41.9%
gastrointestinal hypomotility 35.8%
diarrhoea 27.7%
NCT03036800 · Phase 4 · registry result, not featured evidence · combination
nausea 23.6% (placebo 7%)
constipation 15.7% (placebo 9.3%)
abdominal pain 9% (placebo 2.3%)
NCT03048578 · Phase 4 · registry result, not featured evidence
3.0 mg
gi related 46.7% (placebo 12.9%)
respiratory tract infection 10.9% (placebo 15.1%)
injection site reaction 7.6% (placebo 8.6%)
NCT03038620 · Phase 4 · registry result, not featured evidence
nausea 36% (placebo 4.3%)
upper respiratory infection 32% (placebo 8.7%)
constipation 30% (placebo 0%)
NCT02911818 · Phase 4 · registry result, not featured evidence
nausea 25% (placebo 25%)
NCT01562678 · Phase 4 · registry result, not featured evidence
nausea 16.7% (placebo 11.1%)
vomiting 16.7% (placebo 11.1%)
hgb < 11.5 g/dl 0% (placebo 0%)
NCT03115424 · Phase 3 · registry result, not featured evidence
during study 24.7% (placebo 25%)
NCT03374956 · Phase 3 · registry result, not featured evidence · Obesity · phase 3
3 mg
nausea 25.5% (placebo 11.1%)
vomiting 9.1% (placebo 0%)
diarrhea 7.3% (placebo 0%)
NCT03480022 · Phase 3 · registry result, not featured evidence
diarrhoea 50% (placebo 16.7%)
abdominal pain 30% (placebo 25%)
constipation 15% (placebo 0%)
NCT02527200 · Phase 3 · registry result, not featured evidence
diarrhoea 41.2% (placebo 16.7%)
abdominal pain 17.6% (placebo 25%)
abdominal pain upper 17.6% (placebo 0%)
NCT02527200 · Phase 3 · registry result, not featured evidence
3.0 mg
nausea 29.7% (placebo 11.7%)
diarrhoea 23.1% (placebo 15.2%)
nasopharyngitis 21.5% (placebo 18.3%)
NCT02963922 · Phase 3 · registry result, not featured evidence
3.0 mg
nausea 47.9% (placebo 17.9%)
constipation 30.3% (placebo 18.6%)
vomiting 23.2% (placebo 5%)
NCT02963935 · Phase 3 · registry result, not featured evidence
elective back surgery 2.9% (placebo 0%)
family issues 2.9% (placebo 0%)
protocol deviation 2.9% (placebo 0%)
NCT01784965 · Phase 3 · registry result, not featured evidence
dyspepsia 23.5%
constipation 11.8%
fatigue 11.8%
NCT04883346 · Phase 2 · registry result, not featured evidence
nausea 65.5% (placebo 45.2%)
constipation 41.4% (placebo 9.7%)
heartburn 34.5% (placebo 6.5%)
NCT03158805 · Phase 2 · registry result, not featured evidence
nausea 59.7% (placebo 15.9%)
diarrhea 34.3% (placebo 8.7%)
abdominal pain/discomfort 28.4% (placebo 5.8%)
NCT03523273 · Phase 2 · registry result, not featured evidence
nausea 63.2% (placebo 9.5%)
headache 26.3% (placebo 19%)
abdominal pain/discomfort 21.1% (placebo 9.5%)
NCT02647944 · Phase 2 · registry result, not featured evidence
3.0 mg
nausea 50.5%
nasopharyngitis 40.9%
headache 23.7%
NCT00422058 · Phase 2 · registry result, not featured evidence
1.8 mg / 3.0 mg
nasopharyngitis 37.8%
nausea 37.8%
gastroenteritis 22.2%
NCT00422058 · Phase 2 · registry result, not featured evidence
2.4 mg / 3.0 mg
nasopharyngitis 45.2%
nausea 41.9%
headache 24.7%
NCT00422058 · Phase 2 · registry result, not featured evidence
placebo / 2.4 mg / 3.0 mg
nasopharyngitis 41.8%
nausea 29.6%
headache 23.5%
NCT00422058 · Phase 2 · registry result, not featured evidence
1.2 mg / 3.0 mg
nasopharyngitis 38.9%
nausea 36.8%
influenza 25.3%
NCT00422058 · Phase 2 · registry result, not featured evidence
420 mg
abdominal pain 0% (placebo 0%)
arthralgia 0% (placebo 0%)
back pain 0% (placebo 0%)
NCT03757130 · Phase 1 · registry result, not featured evidence
nausea 50% (placebo 0%)
diarrhoea 33.3% (placebo 0%)
upper respiratory tract infection 33.3% (placebo 16.7%)
NCT03757130 · Phase 1 · registry result, not featured evidence · combination
210 mg
upper respiratory tract infection 50% (placebo 16.7%)
arthralgia 16.7% (placebo 0%)
blood creatine phosphokinase increased 16.7% (placebo 0%)
NCT03757130 · Phase 1 · registry result, not featured evidence
upper respiratory tract infection 66.7% (placebo 16.7%)
constipation 33.3% (placebo 0%)
early satiety 33.3% (placebo 0%)
NCT03757130 · Phase 1 · registry result, not featured evidence · combination
70 mg
back pain 16.7% (placebo 0%)
constipation 16.7% (placebo 0%)
diarrhoea 16.7% (placebo 0%)
NCT03757130 · Phase 1 · registry result, not featured evidence
decreased appetite 62.5% (placebo 0%)
lipase increased 37.5% (placebo 0%)
nausea 25% (placebo 0%)
NCT03757130 · Phase 1 · registry result, not featured evidence · combination
nausea 46.9% (placebo 3.6%)
diarrhoea 34.4% (placebo 14.3%)
headache 34.4% (placebo 10.7%)
NCT03041792 · Phase 1 · registry result, not featured evidence
25 mg once dailyo
nausea 46.6% (placebo 18.6%)
vomiting 30.9% (placebo 5.9%)
nasopharyngitis 21.1% (placebo 26.5%)
NCT05564117 · Phase 3 · registry result, not featured evidence
show 2 more results
50 mg
covid-19 30.6% (placebo 33.3%)
nausea 25.4% (placebo 7.6%)
constipation 20.9% (placebo 9.1%)
NCT05132088 · Phase 3 · registry result, not featured evidence
50 mg once daily
nausea 51.8% (placebo 15.3%)
covid-19 35.6% (placebo 34.5%)
constipation 27.5% (placebo 15%)
NCT05035095 · Phase 3 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for both studies.
  2. bTreatment context has not been resolved for both arms.
  3. cAssessment timepoints differ: 56 weeks versus 68 weeks.
  4. dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  5. eTrial phases differ: Phase 2 versus Phase 3.
  6. fAssessment timepoints differ: 104 weeks versus 64 weeks.
  7. gPopulation context differs: registered conditions differ; age eligibility differs (includes children versus adolescents and adults).
  8. hAssessment timepoints differ: 52 weeks versus 68 weeks.
  9. iAssessment timepoints differ: 104 weeks versus 68 weeks.
  10. jThe reported result categories differ.
  11. kPopulation context differs: registered conditions differ.
  12. lPopulation context differs: eligible sex differs (FEMALE versus ALL).
  13. mAssessment timepoints differ: 32 weeks versus 68 weeks.
  14. nPopulation comparability has not been reviewed for 30 of these studies.
  15. oPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Liraglutide (Saxenda)

Weight Loss Maintenance 80.8% (n=194) vs 47.9% (n=188) placebo @ 56wk3.0 mg
responder rate · % of participants
NCT00781937 · Phase 3 · monotherapy · Obesity · phase 3
Weight Loss 5% 50.5% (n=194) vs 21.9% (n=188) placebo @ 56wk3.0 mg
responder rate · % of participants
NCT00781937 · Phase 3 · monotherapy · Obesity · phase 3
show 4 more results
63.2% (n=2432) vs 27.1% (n=1220) placebo @ 56wk3.0 mg
NCT01272219 · Phase 3 · Obesity · phase 3
49.9% (n=412) vs 13.8% (n=211) placebo @ 56wk3.0 mg
Yes
NCT01272232 · Phase 3 · Obesity, Type 2 Diabetes · phase 3
35.6% (n=204) vs 13.8% (n=211) placebo @ 56wk1.8 mg
Yes
NCT01272232 · Phase 3 · Obesity, Type 2 Diabetes · phase 3
76% (n=58) vs 17% (n=23) placebo @ 52wk
NCT03048578 · Phase 4 · registry result, not featured evidence
Weight Loss 10% 26.1% (n=194) vs 6.3% (n=188) placebo @ 56wk3.0 mg
responder rate · % of participants
NCT00781937 · Phase 3 · monotherapy · Obesity · phase 3
show 3 more results
33.1% (n=2432) vs 10.6% (n=1220) placebo @ 56wk3.0 mg
NCT01272219 · Phase 3 · Obesity · phase 3
23.4% (n=412) vs 4.3% (n=211) placebo @ 56wk3.0 mg
Yes
NCT01272232 · Phase 3 · Obesity, Type 2 Diabetes · phase 3
14.4% (n=204) vs 4.3% (n=211) placebo @ 56wk1.8 mg
Yes
NCT01272232 · Phase 3 · Obesity, Type 2 Diabetes · phase 3
Weight Regain 5% 1.9% (n=207) vs 17.5% (n=206) placebo @ 56wk3.0 mg
responder rate · % of participants
NCT00781937 · Phase 3 · monotherapy · Obesity · phase 3
Weight Regain 10% 0% (n=207) vs 2.9% (n=206) placebo @ 56wk3.0 mg
responder rate · % of participants
NCT00781937 · Phase 3 · monotherapy · Obesity · phase 3
Weight Loss Maintenance 50% 93.2% (n=207) vs 70.9% (n=206) placebo @ 56wk3.0 mg
responder rate · % of participants
NCT00781937 · Phase 3 · monotherapy · Obesity · phase 3
Weight Loss Maintenance 75% 87.4% (n=207) vs 54.4% (n=206) placebo @ 56wk3.0 mg
responder rate · % of participants
NCT00781937 · Phase 3 · monotherapy · Obesity · phase 3
Triglycerides 0.02 vs 0.12 placebo mmol/L @ 56wk3.0 mg
absolute change · mmol/L
NCT00781937 · Phase 3 · monotherapy · Obesity · phase 3
show 1 more result
-0.19 vs -0.01 placebo mmol/L @ 56wk3.0 mg
NCT02963935 · Phase 3 · registry result, not featured evidence
LDL-C 0.24 vs 0.33 placebo mmol/L @ 56wk3.0 mg
absolute change · mmol/L
NCT00781937 · Phase 3 · monotherapy · Obesity · phase 3
show 1 more result
-0.01 vs -0.01 placebo mmol/L @ 56wk3.0 mg
NCT02963935 · Phase 3 · registry result, not featured evidence
Total Cholesterol 0.22 vs 0.33 placebo mmol/L @ 56wk3.0 mg
absolute change · mmol/L
NCT00781937 · Phase 3 · monotherapy · Obesity · phase 3
show 1 more result
-0.01 vs 0 placebo mmol/L @ 56wk3.0 mg
NCT02963935 · Phase 3 · registry result, not featured evidence
Metabolic Syndrome 31.4% (n=194) vs 36.7% (n=188) placebo @ 56wk3.0 mg
responder rate · % of participants
NCT00781937 · Phase 3 · monotherapy · Obesity · phase 3
HOMA-B 8.51% (n=190) vs 6.16% (n=181) placebo @ 56wk3.0 mg
percent change · % of baseline
NCT00781937 · Phase 3 · monotherapy · Obesity · phase 3

+ 171 further endpoints in the CSV export.

Semaglutide (Wegovy tablets)

Weight Loss 15% 47.2% (n=127) vs 0% (n=64) placebo @ 68wk50 mg
event count · % of participants
NCT05132088 · Phase 3 · registry result, not featured evidence · converted to % from 60 Participants as posted
show 2 more results
53.6% (n=317) vs 5.8% (n=295) placebo @ 68wk*50 mg once daily
Yes
NCT05035095 · Phase 3 · registry result, not featured evidence · converted to % from 170 Participants as posted
50% (n=192) vs 5.6% (n=90) placebo @ 64wk*25 mg once daily
Yes
NCT05564117 · Phase 3 · registry result, not featured evidence · converted to % from 96 Participants as posted
Weight Loss 20% 32.3% (n=127) vs 0% (n=64) placebo @ 68wk50 mg
event count · % of participants
NCT05132088 · Phase 3 · registry result, not featured evidence · converted to % from 41 Participants as posted
show 2 more results
33.8% (n=317) vs 2.7% (n=295) placebo @ 68wk*50 mg once daily
Yes
NCT05035095 · Phase 3 · registry result, not featured evidence · converted to % from 107 Participants as posted
29.7% (n=192) vs 3.3% (n=90) placebo @ 64wk*25 mg once daily
Yes
NCT05564117 · Phase 3 · registry result, not featured evidence · converted to % from 57 Participants as posted
IWQOL-Lite-CT Physical Function 7.6 vs 1.9 placebo score @ 68wk50 mg
absolute change · score
NCT05132088 · Phase 3 · registry result, not featured evidence
show 2 more results
14.5 vs 5 placebo score @ 68wk50 mg once daily
NCT05035095 · Phase 3 · registry result, not featured evidence
16.8 vs 8.3 placebo score @ 64wk25 mg once daily
NCT05564117 · Phase 3 · registry result, not featured evidence
Visceral Fat -35.1% (n=50) vs 0.6% (n=20) placebo @ 68wk50 mg
percent change · % of baseline
NCT05132088 · Phase 3 · registry result, not featured evidence
VAT Change Cm2 -0.06 vs 0.02 placebo cm @ 68wk50 mg
absolute change · cm
NCT05132088 · Phase 3 · registry result, not featured evidence
SF-36 Physical Functioning 2.4 vs 0 placebo score @ 68wk50 mg once daily
absolute change · score
NCT05035095 · Phase 3 · registry result, not featured evidence
Fasting Plasma Glucose Change mg/dL -10.3 vs -1.8 placebo mg @ 68wk50 mg once daily
absolute change · mg
NCT05035095 · Phase 3 · registry result, not featured evidence
Fasting Serum Insulin 0.67 vs 0.94 placebo ratio @ 68wk50 mg once daily
absolute change · ratio
NCT05035095 · Phase 3 · registry result, not featured evidence
CRP Change mg/dL 0.42 vs 0.85 placebo ratio @ 68wk50 mg once daily
absolute change · ratio
NCT05035095 · Phase 3 · registry result, not featured evidence
BMI Less Than 30 43.9% (n=294) vs 7.1% (n=268) placebo @ 68wk50 mg once daily
event count · % of participants
NCT05035095 · Phase 3 · registry result, not featured evidence · converted to % from 129 Participants as posted

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Liraglutide (Saxenda)'s landscape · Semaglutide (Wegovy tablets)'s landscape